Logo image of COYA

COYA THERAPEUTICS INC (COYA) Stock Fundamental Analysis

USA - NASDAQ:COYA - US22407B1089 - Common Stock

6.09 USD
+0.08 (+1.33%)
Last: 11/12/2025, 4:30:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to COYA. COYA was compared to 531 industry peers in the Biotechnology industry. While COYA has a great health rating, there are worries on its profitability. COYA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year COYA has reported negative net income.
In the past year COYA has reported a negative cash flow from operations.
In the past 5 years COYA always reported negative net income.
COYA had a negative operating cash flow in each of the past 5 years.
COYA Yearly Net Income VS EBIT VS OCF VS FCFCOYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

COYA has a Return On Assets (-60.80%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -71.84%, COYA is in line with its industry, outperforming 55.74% of the companies in the same industry.
Industry RankSector Rank
ROA -60.8%
ROE -71.84%
ROIC N/A
ROA(3y)-66.21%
ROA(5y)-61.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COYA Yearly ROA, ROE, ROICCOYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

COYA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COYA Yearly Profit, Operating, Gross MarginsCOYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

8

2. Health

2.1 Basic Checks

COYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for COYA has been increased compared to 1 year ago.
COYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COYA Yearly Shares OutstandingCOYA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
COYA Yearly Total Debt VS Total AssetsCOYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

COYA has an Altman-Z score of 8.28. This indicates that COYA is financially healthy and has little risk of bankruptcy at the moment.
COYA's Altman-Z score of 8.28 is amongst the best of the industry. COYA outperforms 80.23% of its industry peers.
COYA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.28
ROIC/WACCN/A
WACC8.77%
COYA Yearly LT Debt VS Equity VS FCFCOYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

COYA has a Current Ratio of 7.43. This indicates that COYA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.43, COYA is in the better half of the industry, outperforming 71.75% of the companies in the same industry.
COYA has a Quick Ratio of 7.43. This indicates that COYA is financially healthy and has no problem in meeting its short term obligations.
COYA has a Quick ratio of 7.43. This is in the better half of the industry: COYA outperforms 72.13% of its industry peers.
Industry RankSector Rank
Current Ratio 7.43
Quick Ratio 7.43
COYA Yearly Current Assets VS Current LiabilitesCOYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

COYA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -66.22%.
Looking at the last year, COYA shows a very negative growth in Revenue. The Revenue has decreased by -95.57% in the last year.
EPS 1Y (TTM)-66.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-89.47%
Revenue 1Y (TTM)-95.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.21%

3.2 Future

COYA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.64% yearly.
COYA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 33.62% yearly.
EPS Next Y-59.38%
EPS Next 2Y-39.1%
EPS Next 3Y-17.77%
EPS Next 5Y13.64%
Revenue Next Year36.24%
Revenue Next 2Y-57.51%
Revenue Next 3Y32.27%
Revenue Next 5Y33.62%

3.3 Evolution

COYA Yearly Revenue VS EstimatesCOYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
COYA Yearly EPS VS EstimatesCOYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COYA. In the last year negative earnings were reported.
Also next year COYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COYA Price Earnings VS Forward Price EarningsCOYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COYA Per share dataCOYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

COYA's earnings are expected to decrease with -17.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-39.1%
EPS Next 3Y-17.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for COYA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COYA THERAPEUTICS INC

NASDAQ:COYA (11/12/2025, 4:30:00 PM)

6.09

+0.08 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-16 2026-03-16/bmo
Inst Owners22.08%
Inst Owner Change-0.03%
Ins Owners1.5%
Ins Owner Change1.69%
Market Cap101.89M
Revenue(TTM)423.50K
Net Income(TTM)-20.34M
Analysts83.08
Price Target16.54 (171.59%)
Short Float %1.91%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-55.53%
Min EPS beat(2)-121.22%
Max EPS beat(2)10.16%
EPS beat(4)3
Avg EPS beat(4)-8.84%
Min EPS beat(4)-121.22%
Max EPS beat(4)38.58%
EPS beat(8)4
Avg EPS beat(8)-13.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-84.93%
Min Revenue beat(2)-90.39%
Max Revenue beat(2)-79.47%
Revenue beat(4)0
Avg Revenue beat(4)-91.75%
Min Revenue beat(4)-100%
Max Revenue beat(4)-79.47%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.58%
PT rev (3m)-3.68%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.23%
EPS NY rev (1m)0.56%
EPS NY rev (3m)2.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 240.58
P/FCF N/A
P/OCF N/A
P/B 3.6
P/tB 3.6
EV/EBITDA N/A
EPS(TTM)-1.23
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.98
OCFYN/A
SpS0.03
BVpS1.69
TBVpS1.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.8%
ROE -71.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.21%
ROA(5y)-61.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.43
Quick Ratio 7.43
Altman-Z 8.28
F-Score2
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-66.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-89.47%
EPS Next Y-59.38%
EPS Next 2Y-39.1%
EPS Next 3Y-17.77%
EPS Next 5Y13.64%
Revenue 1Y (TTM)-95.57%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-95.21%
Revenue Next Year36.24%
Revenue Next 2Y-57.51%
Revenue Next 3Y32.27%
Revenue Next 5Y33.62%
EBIT growth 1Y-120.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-56.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.12%
OCF growth 3YN/A
OCF growth 5YN/A

COYA THERAPEUTICS INC / COYA FAQ

What is the fundamental rating for COYA stock?

ChartMill assigns a fundamental rating of 3 / 10 to COYA.


What is the valuation status for COYA stock?

ChartMill assigns a valuation rating of 0 / 10 to COYA THERAPEUTICS INC (COYA). This can be considered as Overvalued.


What is the profitability of COYA stock?

COYA THERAPEUTICS INC (COYA) has a profitability rating of 1 / 10.


What is the expected EPS growth for COYA THERAPEUTICS INC (COYA) stock?

The Earnings per Share (EPS) of COYA THERAPEUTICS INC (COYA) is expected to decline by -59.38% in the next year.